Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
July 22, 2026 · Shanghai, China and Molndal, Sweden Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results from a Phase 2a study in Europe evaluating vortosiran (RBD4059), Ribo’s siRNA therapy targeting coagulation Factor XI (FXI), in […]
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
July 2, 2026 — Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and […]
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together “Ribo”) announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA-based therapeutic for the treatment of coronary artery disease (CAD). Lately, Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and […]
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
May 12 · Suzhou China Suzhou Ribo Life Science Co., Ltd. (“Ribo”, 06938.HK) today announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine (“Insilico”, 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in target discovery, drug molecule […]
Ribo Advances Clinical Development of FXI siRNA vortosiran with EMA Phase 2b CTA Submission in Venous Thromboembolism, ORBIT-XI-VTE
May 11 2026 – Suzhou, China and Mölndal, Sweden Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (together “Ribo”) today announce the submission of a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for vortosiran (RBD4059), for prevention of venous thromboembolism (VTE). Ribo is thereby expanding their anti-thrombotic […]
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
May 6th, 2026 — Suzhou Ribo Life Science Co., Ltd. (HKEX stock code: 6938) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure, collectively referred to as “Ribo”) today announced the achievement of a further milestone. This marks the third key milestone achieved in the research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, […]
Ribocure in Swedish media
We are grateful for the opportunity to be featured in SVT’s Victoria’s Hjärta and related national news coverage. This highlights our work on preventive, targeted treatments for cardiovascular disease using siRNA, and helps raise public awareness of future therapies and the impact of clinical research. If you want read more about our clinical studies and […]
Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillation
April 14 – Suzhou, China and Mölndal, Sweden Suzhou Ribo Life Science (6938.HK) and its subsidiary Ribocure Pharmaceuticals AB, (together “Ribo”) today announced the successful submission of a Phase 2b Clinical Trial Application (CTA) to the European Medicine Agency (EMA) for vortosiran (RBD4059), the world’s first and most advanced siRNA therapy targeting Factor XI (FXI), for stroke prevention […]
Ribo Appoints CMO and CBO to Empower Global R&D and Partnerships
March 26, 2026 – Suzhou Ribo Life Science Co., Ltd. (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) today announced two key executive appointments, as approved by the Board of Directors; Dr. Anders Gabrielsen, former Vice President and Global Head of Clinical Development, has been appointed Chief Medical Officer (CMO), and will oversee […]
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
Suzhou Ribo Life Science Co., Ltd. (“Ribo” or “the Company”, Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences. Following Ribo’s success of the RiboGalSTAR™ targeting liver specific genes with seven programs in […]
